At present, the gold standard genetic test for SMA diagnosis is multiplex ligation‐dependent probe amplification (MLPA) of SMN1 and SMN2 although it cannot identify silent carriers (2 + 0) nor subtle mutations in SMN1 (false‐negative rate of approximately 5%). Here, SMN2 is linked to proximal spinal muscular atrophy.